Ligufalimab, a novel anti-CD47 antibody with no hemagglutination demonstrates both monotherapy and combo antitumor activity

BACKGROUND: CD47 is a widely expressed transmembrane glycoprotein that delivers an antiphagocytic signal on macrophages through its interaction with SIRPα. CD47 is highly expressed in cancer cells and its overexpression is correlated with poor prognosis. CD47 blocking antibodies are actively being d...

Descripción completa

Detalles Bibliográficos
Autores principales: Qu, Tailong, Zhong, Tingting, Pang, Xinghua, Huang, Zhaoliang, Jin, Chunshan, Wang, Zhongmin Maxwell, Li, Baiyong, Xia, Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Basic Tumor Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9717234/
https://www.ncbi.nlm.nih.gov/pubmed/36450383
http://dx.doi.org/10.1136/jitc-2022-005517

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9717234/
https://www.ncbi.nlm.nih.gov/pubmed/36450383
http://dx.doi.org/10.1136/jitc-2022-005517

Ejemplares similares